
First-Line Amivantamab With Lazertinib Boosts OS in EGFR-Mutated NSCLC
Frontline treatment with amivantamab-vmjw (Rybrevant) plus lazertinib (Lacluze) significantly increased overall survival (OS) vs osimertinib (Tagrisso) in patients with EGFR-mutated non-small cell lung cancer (NSCLC), per updated data from the phase 3 …